SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARRIS - Another partner
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: biopicker who wrote (254)11/23/1997 1:44:00 PM
From: Andrew H  Read Replies (1) of 353
 
Thanks biopicker for a most excellent and articulate analysis of Axys. I agree with much of what you say. Yes, the company has tremendous potential. Yes, ARRS is oversold which is what the market often does to biotechs that will not have a product on the market for 4-5 years. Too many years of uncertainty. Yes, it has gone down for the wrong reasons.

As for Wall Street understanding it, that may just have to wait until profitability is on the horizon. I hope you are right and I am wrong.

As for Walker maximizing shareholder value, I am wondering just what that means. ARRS is sitting just above its 104 week lows. The value may be there somewhere, but for the shareholders that have been holding for two years, it must be a real leap of faith.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News